MEDICENNA THERAPEUTICS CORP (MDNA) Stock Earnings & Estimates
NASDAQ:MDNA - CA58490H1073 - Common Stock
0.157 USD
-0.02 (-13.16%)
0.1565 USD
0 (-0.32%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 21.74% | N/A 5,088.05% | N/A 20.67% | N/A 48.63% | N/A 46.37% | |||||||||
| EBITDA YoY % growth | N/A | -80K | -7.42M -9,175.00% | -4.72M 36.39% | -8.23M -74.36% | -17.36M -110.94% | -22.435M -29.23% | -16.299M 27.35% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -200K | -90K 55.00% | -7.43M -8,155.56% | -4.73M 36.34% | -8.24M -74.21% | -17.4M -111.17% | -22.473M -29.16% | -16.303M 27.46% | N/A -25.39% | N/A -23.07% | N/A -15.89% | N/A 75.31% | N/A 285.98% | N/A 122.21% | N/A 83.37% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -0.22 40.09% | -0.26 -18.18% | -0.35 -34.62% | -0.42 -20.00% | -0.19 54.76% | N/A -26.16% | N/A -21.99% | N/A -5.35% | N/A 299.80% | N/A | N/A | N/A |
All data in CAD
| Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.07 -68.30% | -0.08 -277.40% | -0.07 -12.20% | -0.08 -104.00% | -0.08 -21.21% | -0.08 -8.11% | -0.08 -13.64% |
| Revenue Q2Q % growth | |||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5.314M -12.27% | -5.929M -20.48% | -5.439M -134.54% | -6.229M -39.69% | -6.307M -18.69% | -6.639M -11.98% | -7.38M -35.69% |
All data in CAD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2024 Q2Q % growth | -0.04 42.86% | -0.06 | 0.02 | 36.41% |
| Q4 2023 Q2Q % growth | -0.06 | -0.08 | 0.02 | 29.41% |
| Q3 2023 Q2Q % growth | -0.02 77.78% | -0.09 | 0.07 | 78.61% |
| Q2 2023 Q2Q % growth | -0.04 73.33% | -0.07 | 0.03 | 41.90% |
| Q1 2023 Q2Q % growth | -0.07 41.67% | -0.08 | 0.01 | 14.22% |
| Q4 2022 Q2Q % growth | -0.06 45.45% | -0.11 | 0.05 | 44.10% |
| Q3 2022 Q2Q % growth | -0.09 18.18% | -0.13 | 0.04 | 30.01% |
| Q2 2022 Q2Q % growth | -0.15 -87.50% | -0.12 | -0.03 | -26.18% |
| Q1 2022 Q2Q % growth | -0.12 -140.00% | -0.10 | -0.02 | -17.65% |
| Q4 2021 Q2Q % growth | -0.11 -57.14% | -0.11 | 0.00 | -1.74% |
| Q3 2021 Q2Q % growth | -0.11 -57.14% | -0.07 | -0.04 | -59.77% |
| Q2 2021 Q2Q % growth | -0.08 -14.29% | -0.08 | 0.00 | 4.93% |
| Q1 2021 Q2Q % growth | -0.05 | -0.05 | 0.00 | -8.93% |
| Q4 2020 Q2Q % growth | -0.07 -133.33% | -0.05 | -0.02 | -52.51% |
| Q3 2020 Q2Q % growth | -0.07 | -0.07 | 0.00 | 6.41% |
| Q2 2020 Q2Q % growth | -0.07 -40.00% | -0.07 | 0.00 | 1.96% |
| Q1 2020 Q2Q % growth | -0.05 -66.67% | -0.08 | 0.03 | 38.73% |
| Q4 2019 Q2Q % growth | -0.03 | -0.11 | 0.08 | 73.26% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2021 Q2Q % growth | 382.5K | -382.5K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 1% | 5.71% | 0% | 3.42% |
| Revenue | N/A | N/A | 0% | -16.67% |